Development of a method to quantify clindamycin in vitreous humor of rabbits' eyes by UPLC-MS/MS: Application to a comparative pharmacokinetic study and in vivo ocular biocompatibility evaluation

Journal of Pharmaceutical and Biomedical Analysis

Volumn 102, Issue , 2015, Pages 346-352

  Fernandes Cunha, Gabriella M ^a   Gouvea, Dayana Rubio ^b   Fulgêncio, Gustavo de Oliveira ^a   Rezende, Cíntia M F ^a   da Silva, Gisele Rodrigues ^c   Bretas, Juliana M ^a   Fialho, Sílvia Ligório ^d   Lopes, Norberto Peporine ^b   Silva Cunha, Armando ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO JOÃO DEL REI   (Brazil)

^d Ezequiel Dias Foundation   (Brazil)

Author keywords

Biocompatibility; Clindamycin hydrochloride; Ocular toxoplasmosis; Pharmacokinetic; UPLC MS MS

Indexed keywords

CLINDAMYCIN; LINCOMYCIN; POLYGLACTIN; DRUG IMPLANTS;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BIOCOMPATIBILITY; CLINICAL EXAMINATION; COMPARATIVE STUDY; CONTROLLED STUDY; DEVELOPMENT; DRUG IMPLANT; DRUG IMPLANTATION; EXPERIMENTAL RABBIT; EYE INFLAMMATION; IN VIVO STUDY; INTRAOCULAR PRESSURE; MALE; MAXIMUM PLASMA CONCENTRATION; MEASUREMENT ACCURACY; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; SUSTAINED DRUG RELEASE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXOPLASMOSIS; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VITREOUS BODY; ANIMALS; CHEMISTRY; CHROMATOGRAPHY, LIQUID; DRUG EFFECTS; DRUG EVALUATION, PRECLINICAL; DRUG IMPLANTS; EYE; INTRAVITREAL INJECTIONS; MATERIALS TESTING; METHODS; RABBITS;

ANIMALS; CHROMATOGRAPHY, LIQUID; CLINDAMYCIN; DRUG EVALUATION, PRECLINICAL; DRUG IMPLANTS; EYE; INTRAVITREAL INJECTIONS; MALE; MATERIALS TESTING; RABBITS; TANDEM MASS SPECTROMETRY; VITREOUS BODY;

EID: 84908689560     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2014.08.023     Document Type: Article

References (25)

1. Dodds E.M. Ocular toxoplasmosis: clinical presentations, diagnosis and therapy. Focal Points: Clinical Modules for Ophthalmologists 1999, 1-14. American Academy of Ophthalmology, San Francisco, CA.
2. Holland G.N. Ocular toxoplasmosis: a global reassessment. Part II: disease manifestation and management. Am. J. Ophthalmol. 2004, 137:1-17.
3. Soheilian M., Heidari K., Yazdani S., Shahsavari M., Ahmadieh H., Dehghan M. Patterns of uveitis in a tertiary eye care center in Iran. Ocul. Immunol. Inflamm. 2004, 12:297-310.
4. Martinez C.E., Zhang D., Conway M.D., Peyman G.A. Successful management of ocular toxoplasmosis during pregnancy using combined intraocular clindamycin and dexamethasone with systemic sulfadiazine. Int. Ophthalmol. 1998, 22:85-88.
5. Kishore K., Conway M.D., Peyman G.A. Intravitreal clindamycin and dexamethasone for toxoplasmic retinochoroiditis. Ophthal. Surg. Lasers 2001, 32:183-192.
6. Sobrin L., Kump L.I., Fosters C.S. Intravitreal clindamycin for toxoplasmosis retinochoroiditis. Retina 2007, 27:952-957.
7. Soheilian M., Ramezani A., Azimzadeh A., Sadoughi M.M., Dehghan M.H., Shahghdami R., Yaseri M., Peyman G.A. Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis. Ophthalmology 2011, 118:134-141.
8. Hovakimyan A., Cunningham E.T. Ocular toxoplasmosis. Ophthalmol. Clin North Am. 2002, 15:327-332.
9. Stanford M.R., See S.E., Jones L.V., Gilbert R.E. Antibiotics for toxoplasmic retinochoroiditis: an evidence-based systematic review. Ophthalmology 2003, 110:926-931. (quiz 931-2).
10. da Silva G.R., Fialho S.L., Siqueira R.C., Jorge R., Silva-Cunha A.S. Implant as drug delivery devices for the treatment of eye diseases. Braz. J. Pharmaceut. Sci. 2010, 46:586-595.
11. Kunou N., Ogura Y., Hashizoe M., Honda Y., Hyon S., Ikada Y. Controlled intra-ocular delivery of ganciclovir with use of biodegradable scleral implant in rabbits. J. Control. Release 1995, 37:143-150.
12. Dong X., Chen N., Xie L., Wang S. Prevention of experimental proliferative vitreoretinopathy with a biodegradable intravitreal drug deliver system of all-trans retinoic acid. Retina 2006, 26:210-213.
13. Amo E.M., Urtti A. Current and future ophthalmic drug delivery systems: a shift to the posterior segment. Drug Discov. Today 2008, 13:135-143.
14. Marchi I., Viette V., Badoud F., Fathi M., Saugy M., Rudaz S., Veuthey J.L. Characterization and classification of matrix effects in biological samples analyses. J. Chromatogr. A 2010, 1217:4071-4078.
15. ICH Validation of Analytical Procedures: Definitions and Terminology 1996, ICH, Geneva.
16. ®40). J. Pharm. Biomed. Anal. 2014, 89:24-27.
17. Cho S.H., Im H.T., Park W.S., Ha Y.H., Choi Y.W., Lee K.T. Simple method for the assay of clindamycin in human plasma by reversed-phase high-performance liquid chromatography with UV detector. Biomed. Chromatogr. 2005, 19:783-787.
18. Sanki U.K.U., Mandal B.K.B.K., Chandrakala V.V. Comparative pharmacokinetics study of two different clindamycin capsule formulations: a randomized, two-period, two-sequence, two-way crossover clinical trial in healthy volunteers. Arzneimittel-Forsch. 2011, 61:538-543.
19. Li J., Wang N., Zhang Z.J., Tian Y., Tang W., Chen Y. Pharmacokinetics and bioequivalence study of clindamycin hydrochloride formulations after single-dose administration in healthy Chinese male volunteers. Arzneimittel-Forsch. 2008, 58:358-362.
20. Catena E., Perez G., Sadaba B., Azanza J.R., Campanero M.A. A fast reverse-phase high performance liquid chromatographic tandem mass spectrometry assay for the quantification of clindamycin in plasma and saliva using a rapid resolution package. J. Pharm. Biomed. Anal. 2009, 50:649-654.
21. Kavitha N., Noordin R., Chan K.L., Sasidharan S. In vitro anti-Toxoplasma gondii activity of root extract/fractions of Eurycoma longifolia jack. BMC Complement. Alter. Med. 2012, 91:1-8.
22. Hwang Y.S., Chiang P.R., Hong W.H., Chiao C.C., Chu I.M., Hsiue H., Shen C.R. Study in vivo intraocular biocompatiblity of in situ gelation hydrogels: poly(2-ethyl oxazoline)-block-poly(e-caprolactone)-block-poly(2-ethyloxazoline) copolymer, matrigel and pluronic F127. PLoS One 2013, 8. 10.1371/journal.pone.0067495.
23. Zou L., Nair A., Weng H., Tsai Y.T., Hu Z., Tang L. Intraocular pressure changes: an important determinant of the biocompatibility of intravitreal implants. PLoS One 2011, 6. 10.1371/journal.pone.0028720.
24. Lai J.H. Biodegradable in situ gelling delivery systems containing pilocarpine as new antiglaucoma formulations: effect of a mercaptoacetic acid/N-isopropylacrylamide molar ratio. Drug Des. Dev. Ther. 2013, 7:1273-1285.
25. Allen R.C., Suhler E.B., Flaxel C.J., Chen Z., Choi D. Long-term follow-up patients treated with multiple fluocinolone acetonide implants for noninfectious uveitis. J. Ophthal. Inflamm. Infect. 2012, 2:177-182.